Physiomics plc announced that it has been awarded a further contract by existing client, Numab Therapeutics ("Numab"). The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 GBX | 0.00% | 0.00% | -21.88% |
May. 03 | Physiomics warns large contracts taken longer than expected | AN |
May. 03 | AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.88% | 2.15M | |
-0.07% | 137B | |
+21.20% | 77.04B | |
-9.96% | 40.58B | |
+14.34% | 38.07B | |
-5.46% | 17.25B | |
+12.87% | 15.32B | |
+9.51% | 10.44B | |
-10.73% | 4.71B | |
-35.15% | 3.96B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Announces Contract Award